Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Obesity Treatment Landscape 2026: Obesity Competitive Landscape and Clinical Trial Analysis 2026 Examines 200+ Companies and 200+ Drugs

globenewswire.com
LLY Eli Lilly and Company is highlighted for its obesity treatments, Orforglipron (marketed, oral GLP-1 agonist) and Retatrutide (investigational, triple agonist). Both show promising results in weight reduction and metabolic improvement, indicating strong pipeline and market potential. NVO Novo Nordisk's Wegovy (semaglutide) is a key GLP-1 receptor agonist for chronic weight management. The article mentions its subcutaneous injection and the FDA approval of an oral tablet formulation, which achieved significant weight loss in trials, underscoring its market leadership and product success. NBIX Neurocrine Biosciences is developing NBIP-1968, a long-acting GLP-1/GIP/glucagon receptor triple agonist in Phase I trials. This indicates active development in the promising obesity treatment space. WVE Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA candidate targeting Activin E for fat loss. The Phase I/IIa trial is assessing its potential in promoting fat loss while preserving lean mass. ALV Alveus Therapeutics is investigating ALV-100, a bifunctional GIP receptor antagonist and GLP-1 receptor agonist fusion protein, in a Phase Ib study. This dual-action approach suggests potential for effective weight management. PFE Pfizer is mentioned as a key company evaluated in the report, but no specific details on their obesity pipeline or performance are provided in the article excerpt. ABBV AbbVie is listed as a prominent company evaluated in the report, but the article does not provide specific details about their involvement or progress in the obesity treatment market. AMGN While not explicitly mentioned, Amgen is a major player in biotech and could be involved in the obesity space. However, the article does not provide specific information about their current activities or pipeline related to obesity. VKTX Viking Therapeutics is developing VK2735, an investigational GLP-1/GIP receptor agonist. The article lists it as a key product, suggesting it is a notable candidate in the obesity pipeline. ALNY Alnylam Pharmaceuticals is mentioned, and ALN-6222 is listed as a key product. While details are scarce, their involvement in RNAi therapeutics suggests potential innovation in obesity treatment.

Obesity Treatment Landscape 2026: Obesity Competitive Landscape and Clinical Trial Analysis 2026 Examines 200+ Companies and 200+ Drugs Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Obesity - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering.

The "Obesity - Competitive Landscape and Clinical Trial Analysis, 2026" report provides a comprehensive global assessment of more than 200 companies and 200 marketed and investigational obesity drugs. The report evaluates the obesity therapeutics pipeline by development stage, product type, molecule type and route of administration while also reviewing inactive and discontinued candidates.

Designed to support pharmaceutical companies, biotechnology developers, investors, researchers and other healthcare stakeholders, the report delivers detailed obesity market intelligence covering clinical development, competitive positioning, licensing agreements, collaborations, acquisitions and emerging treatment technologies.

Global Obesity Therapeutics Overview

Obesity is a chronic, relapsing, adiposity-based disease associated with substantial metabolic, cardiovascular, hepatic, respiratory and musculoskeletal complications. Clinical assessment increasingly considers body-fat distribution, central adiposity, metabolic dysfunction and obesity-related organ impairment alongside body mass index.

Obesity development involves interactions among genetic susceptibility, neuroendocrine regulation, dietary patterns, energy imbalance, physical inactivity, environmental influences, medications and socioeconomic conditions. Excess adipose tissue contributes to chronic inflammation, insulin resistance, altered adipokine signalling and metabolic dysfunction, increasing the risk of type 2 diabetes, cardiovascular disease, fatty liver disease and sleep apnoea.

Clinical management combines nutritional intervention, physical activity and behavioural support with pharmacotherapy when appropriate. Current treatment options include GLP-1 receptor agonists, dual GLP-1/GIP therapies and other approved anti-obesity medicines. Metabolic or bariatric surgery remains an important option for selected patients with severe or complicated obesity.

Key Obesity Clinical Trial and Pipeline Developments

Selected Marketed Obesity Therapies

Orforglipron - Eli Lilly and Company: Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist developed for obesity treatment. It is designed to improve metabolic control and support weight reduction without injectable administration or fasting requirements. According to the report, the UK Medicines and Healthcare products Regulatory Agency authorised orforglipron for adults with insufficiently controlled obesity in August 2026.

Wegovy - Novo Nordisk: Wegovy, or semaglutide, is a GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. In the United States, the therapy is available as a once-weekly subcutaneous injection, while a once-daily 25 mg oral tablet received FDA approval in December 2025. The oral formulation achieved approximately 17% mean weight loss at 64 weeks in the Phase III OASIS 4 trial.

Leading Obesity Pipeline Therapies

Retatrutide - Eli Lilly and Company: Retatrutide is an investigational once-weekly injectable agonist targeting GIP, GLP-1 and glucagon receptors. Phase III trials have reported substantial reductions in body weight and improvements in metabolic measures. Retatrutide remains investigational and is not approved for obesity treatment.

Enicepatide/CT-388 - Roche: Enicepatide is an investigational once-weekly dual GLP-1/GIP receptor agonist for chronic weight management. Phase II studies reported mean body-weight reductions of up to 22.7% at 48 weeks at the highest dose. Phase III evaluation is underway in adults with obesity or overweight, with or without type 2 diabetes.

KDS2010 - NeuroBiogen: KDS2010 is an investigational oral reversible monoamine oxidase-B inhibitor being studied as a non-incretin obesity treatment. A Phase IIa study is evaluating multiple doses in adults with overweight or obesity, including effects on body weight, body composition and metabolic parameters.

WVE-007 - Wave Life Sciences: WVE-007 is an investigational INHBE-targeting GalNAc-siRNA candidate intended to reduce Activin E signalling and promote fat loss while preserving lean mass. The Phase I/IIa INLIGHT trial is assessing safety, pharmacokinetics, pharmacodynamics, body composition and weight-related outcomes.

ASC36 - Ascletis Pharma: ASC36 is a next-generation amylin receptor peptide agonist designed for dosing from once monthly to once quarterly. Ascletis initiated a US Phase I study in August 2026 following FDA clearance of its Investigational New Drug application.

NBIP-1968 - Neurocrine Biosciences: NBIP-1968 is a long-acting GLP-1/GIP/glucagon receptor triple agonist designed for once-weekly subcutaneous administration. A Phase I first-in-human study is evaluating its safety and tolerability across adults in different BMI categories.

ALV-100 - Alveus Therapeutics: ALV-100 is an investigational bifunctional GIP receptor antagonist and GLP-1 receptor agonist fusion protein. A Phase Ib study is assessing safety, tolerability, pharmacokinetics, pharmacodynamics and body-weight effects in adults with overweight or obesity, with or without type 2 diabetes.

Obesity Competitive Landscape and Commercial Analysis

The report compares obesity companies and therapies by mechanism, development stage, molecule type and administration route. Its commercial assessment examines company-to-company collaborations, industry-academic partnerships, licensing arrangements, acquisitions and transaction-value trends. This analysis helps identify competitive strategies, business development activity and areas of unmet need across the global obesity treatment market.

The clinical trial assessment covers trial status, development phase, therapeutic category, participant age, enrollment, completion year and endpoint status. Trial-design analysis evaluates allocation, interventional models, masking and recruitment status. Sponsor and geographic analysis reviews leading sponsors, country-level trial activity, development stages and the distribution of obesity therapies across major markets.

Key Companies Covered

Prominent companies evaluated include Eli Lilly and Company, Novo Nordisk, Roche, Neurocrine Biosciences, Ascletis Pharma, Wave Life Sciences, MBX Biosciences, iBio, Viking Therapeutics, Pfizer, AbbVie, Boehringer Ingelheim, Merck Sharp & Dohme, Hanmi Pharmaceutical, Alveus Therapeutics, Alnylam Pharmaceuticals, Genexine, Syntis Bio and multiple emerging biotechnology and pharmaceutical developers.

Key Obesity Products Covered

Major products assessed include orforglipron, retatrutide, Wegovy, NBIP-1968, ASC36, WVE-007, GX-G6, UBT251, CT-388, MBX 4291, IBIO-600, VK2735, berobenatide, SA030, HDM1005, HS-20136-2, BGM0504, ABBV-295, BI 3034701, CG-0416, MK-4082, HM17321, ALV-100, SYNT-101 and ALN-6222.

Strategic Questions Addressed

The "Obesity - Competitive Landscape and Clinical Trial Analysis, 2026" report offers a detailed resource for understanding the rapidly evolving obesity drug pipeline, clinical trial environment and global competitive landscape. It provides actionable intelligence on established market leaders, emerging biotechnology companies, next-generation incretin therapies and differentiated mechanisms that may influence the future of obesity treatment.

Key Topics Covered:

Introduction

Executive Summary

Obesity: Overview

Obesity -Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Obesity: Company and Product Profiles (Marketed Therapies)

Eli Lilly and Company

Orforglipron

Obesity: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Eli Lilly and Company

Retatrutide

Mid Stage Products (Phase II)

NeuroBiogen Co., Ltd

KDS2010

Early Stage Products (Phase I)

Neurocrine Biosciences

NBIP-'1968

Preclinical Stage Products

Discovery Stage Products

Unknown Stage Products

Therapeutic Assessment

Clinical Trial Assessment

Clinical Trial Analysis

Clinical Trial Design Analysis

Sponsor and Geographical Analysis

Inactive Products

Obesity- Unmet needs

Obesity - Market drivers and barriers

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/8nkomq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.